Sanofi (SASY) will buy U.S. vaccines company Dynavax Technologies (DVAX) for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday, a deal that will give it access to an approved hepatitis B vaccine.
December 24, 2025 - 16:08
By Pharos Investment Advisors Comments are Off
Sanofi (SASY) will buy U.S. vaccines company Dynavax Technologies (DVAX) for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday, a deal that will give it access to an approved hepatitis B vaccine.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved